The Growing Wait for Life-Saving Drugs: A Critical Look at South Korea’s Healthcare System
Patients battling cancer and rare diseases in South Korea face an increasingly frustrating reality: a lengthy wait to access newly approved medications. A recent investigation reveals that the time between a drug’s regulatory approval and its inclusion on the national health insurance list – making it affordable for patients – averages nearly three years.
The Delays: A Breakdown of the Process
The process for new drug approval and coverage involves multiple stages: approval by the Ministry of Food and Drug Safety (MFDS), application for listing by pharmaceutical companies, assessment of cost-effectiveness by the Health Insurance Review and Evaluation Service (HIRA), price negotiations with the National Health Insurance Service (NHIS), and finally, review and approval by the Health Insurance Policy Deliberation Committee. While regulations stipulate a 120-150 day evaluation period by HIRA, the actual timeframe often extends significantly.
Anticancer Drugs and Rare Disease Treatments: The Longest Waits
The analysis, conducted by the Korea Patient Advocacy Coalition, examined 32 anticancer drugs and 20 treatments for rare diseases approved between 2021 and 2025. Anticancer drugs take an average of 1 year and 10 months (659 days) to develop into covered by insurance. Treatments for rare diseases face even longer delays, averaging 2 years and 11 months, with some cases exceeding 3 years and 10 months.
Pharmaceutical Company Tactics and Administrative Bottlenecks
The delays aren’t solely due to bureaucratic hurdles. The report suggests that pharmaceutical companies sometimes strategically delay submitting applications for listing, aiming to maximize profits during initial exclusivity periods. Administrative bottlenecks within the review and approval process contribute to the extended timelines. The time from MFDS approval to a company’s listing application averages 191 days (approximately 6 months).
The Human Cost of Delayed Access
For patients with serious illnesses, these delays can be devastating. The inability to access timely treatment can lead to disease progression, reduced quality of life, and, in some cases, preventable deaths. The financial burden of paying for medications out-of-pocket can also be crippling for many families.
Calls for Reform: Expedited Pathways and Shared Responsibility
The Korea Patient Advocacy Coalition is advocating for the swift implementation of a “fast-track listing with post-market evaluation” system, particularly for rare disease treatments. This approach would prioritize patient access to needed medications while allowing for ongoing monitoring of effectiveness and cost-effectiveness. They also emphasize the need for pharmaceutical companies to demonstrate a greater sense of responsibility and submit applications promptly.
Anki Jong, President of the Korea Patient Advocacy Coalition, stressed that pharmaceutical companies should not prioritize profit maximization over patient well-being, urging them to submit applications for listing quickly and engage in constructive price negotiations.
The Broader Trend: AI and Data Transforming Biohealth
These challenges occur against a backdrop of rapid transformation in the biohealth industry. Globally, the sector is shifting from a traditional pharmaceutical focus to a data and AI-driven platform model. The global biohealth market is projected to grow from approximately $1.7 trillion in 2024 to $2.8 trillion by 2030, fueled by advancements in AI-powered drug discovery and personalized medicine.
Did you grasp? The global digital healthcare market was valued at approximately $240.85 billion in 2023 and is expected to reach $1.635 trillion by 2033, growing at a CAGR of 21.11%.
Future Outlook: Innovation and Regulatory Adaptation
South Korea is actively investing in AI and digital health technologies, with initiatives like the establishment of the ‘Lilly Gateway Labs’ open innovation hub in Songdo, a partnership between Samsung Biologics and Eli Lilly. This hub, expected to be completed in 2027, will provide resources and support for biotech startups. However, regulatory frameworks must adapt to keep pace with these innovations to ensure patients benefit from these advancements without undue delay.
Pro Tip: Stay informed about new drug approvals and health insurance coverage changes through official government websites and patient advocacy groups.
FAQ
- How long does it take for a new drug to be covered by health insurance in South Korea? On average, it takes nearly three years. Anticancer drugs take approximately 1 year and 10 months, while rare disease treatments can take over 2 years and 11 months.
- What are the main reasons for the delays? Pharmaceutical company strategies, administrative bottlenecks in the review process, and lengthy evaluation periods contribute to the delays.
- What is being done to address these issues? The Korea Patient Advocacy Coalition is advocating for expedited listing pathways and greater responsibility from pharmaceutical companies.
Explore more articles on biohealth and industry IT on our website.
